Intravitreal anti-vascular endothelial growth factor monotherapy in age-related macular degeneration with submacular hemorrhage.

Sci Rep · 2023 · PMC10081992 · PMID 37029159

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, in the VH + group, the post-injection BCVAs at 6 and 12 months did not change significantly compared with baseline ( P = 1.000, and P = 0.138 at 6 and 12 months, respectively) and the VH + group showed a trend toward visual worsening during the follow-up period.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.